Mar 9, 2022

Regenerative medical devices company, Tissue Regenix Group, has signed an exclusive agreement to have its OrthoPure XT product distributed in Italy. The Leeds-based business has struck the deal with Geistlich Biomaterials Italia, a subsidiary company of Geistlich Pharma AG, a global company with a focus on regenerative products for bone, cartilage and tissue. OrthoPure XT uses Tissue Regenix’s patented dCell® technology and is the only available non-human biologic graft indicated for certain ligament reconstruction procedures. It was commercially launched in December 2020 after being awarded a CE Mark for revision of anterior cruciate ligament reconstruction procedures and reconstruction of other knee ligaments. The multi-year distribution deal covers Italy currently but also has the potential for extension to wider geographies. As part of the agreement, Geistlich has committed to advance the clinical science surrounding OrthoPure XT, which will be conducted at some of the leading institutions by clinicians in Italy. Daniel Lee, chief executive officer of Tissue Regenix, said: “We are pleased to partner with Geistlich for our commercial efforts in Italy. “Geistlich is a leader in regenerative products, so our commitments are aligned in delivering innovative products to advance patient care. “We are excited to work with them to build the clinical experience with OrthoPure XT and introduce this transformative product to the Italian medical community.” Filippo Baldini, national sales manager for Geistlich Biomaterials Italia, added: “Geistlich is excited to bring this new technology to the Italian market and serve the patient’s needs with this innovative solution.” Previous Article